Skip to main content
. Author manuscript; available in PMC: 2011 Jul 18.
Published in final edited form as: Oncogene. 2010 Jan 18;29(14):2047–2059. doi: 10.1038/onc.2009.486

Figure 6.

Figure 6

Downregulation of tyrosine kinase B (TrkB) suppresses tumor growth in an orthotopic model of head and neck squamous cell carcinoma (HNSCC). (a) In vivo bioluminescence reveals suppression of tumor growth in orthotopically implanted cells harboring short hairpin RNA (shRNA) targeting TrkB (OSC19-shRNA-TrkB; n = 8) or a non-targeting construct (OSC19-shRNA-NT; n = 9). Results are representative of three independent experiments. (b) Tumor size is inhibited by 62% in tumors with TrkB knockdown. (c), Hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) analysis of tumors. IHC confirmed knockdown of TrkB in the shRNA-TrkB primary tumors compared with shRNA-NT tumors ( ×200, inset: ×50). Alterations in E-cadherin, TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling), Ki67 and proliferating cell nuclear antigen (PCNA) were confirmed by IHC. NT, non targeting.